We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-2.2%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$11.9M
Cap. Flow
+$42.8M
Cap. Flow %
11.33%
Top 10 Hldgs %
55.17%
Holding
61
New
9
Increased
14
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.2M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.7M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$10.9M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15.5M
4
HALO icon
Halozyme
HALO
+$12.5M
5
AMGN icon
Amgen
AMGN
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
26
Aurinia Pharmaceuticals
AUPH
$2.19B
$3.88M 1.02%
298,500
+220,000
+280% +$3.19M
STRO icon
27
Sutro Biopharma
STRO
$353M
$3.17M 0.84%
13,933
– –
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.7M 0.71%
79,456
– –
CRSP icon
29
CRISPR Therapeutics
CRSP
$5.74B
$2.68M 0.71%
22,000
– –
SRPT icon
30
Sarepta Therapeutics
SRPT
$2.28B
$2.35M 0.62%
31,500
– –
RARE icon
31
Ultragenyx Pharmaceutical
RARE
$2.59B
$2.29M 0.6%
+20,100
New +$2.74M
BPMC
32
DELISTED
Blueprint Medicines
BPMC
$1.9M 0.5%
19,500
– –
IOVA icon
33
Iovance Biotherapeutics
IOVA
$3.74B
$1.84M 0.49%
58,000
– –
ALLK
34
DELISTED
Allakos
ALLK
$1.8M 0.48%
15,700
– –
ASND icon
35
Ascendis Pharma A/S
ASND
$16.4B
$1.77M 0.47%
13,800
– –
NBP
36
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$1.69M 0.45%
+35,000
New +$1.9M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
$1.61M 0.43%
+21,500
New +$1.76M
ACAD icon
38
Acadia Pharmaceuticals
ACAD
$5.12B
$1.53M 0.41%
59,514
-426,486
-88% -$18.8M
ARNA
39
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.46M 0.39%
+21,000
New +$1.62M
DYN icon
40
Dyne Therapeutics
DYN
$4.87B
$1.45M 0.38%
+93,886
New +$1.82M
HALO icon
41
Halozyme
HALO
$12.1B
$1.44M 0.38%
34,633
-273,000
-89% -$12.5M
EXAS
42
DELISTED
Exact Sciences
EXAS
$1.41M 0.37%
10,700
– –
NKTR icon
43
Nektar Therapeutics
NKTR
$2.55B
$1.34M 0.35%
4,467
– –
ORIC icon
44
Oric Pharmaceuticals
ORIC
$1.42B
$1.3M 0.34%
53,000
– –
INSM icon
45
Insmed
INSM
$26.5B
$1.14M 0.3%
33,600
– –
AGIO icon
46
Agios Pharmaceuticals
AGIO
$2.05B
$1.11M 0.29%
21,500
– –
APLS
47
DELISTED
Apellis Pharmaceuticals
APLS
$1M 0.26%
+23,400
New +$1.11M
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$935K 0.25%
94,600
– –
GBT
49
DELISTED
Global Blood Therapeutics, Inc.
GBT
$888K 0.23%
21,800
– –
GMDA
50
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$862K 0.23%
+107,000
New +$982K
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2021 Portfolio in Review

As of Q1 2021, International Biotechnology Trust held 61 positions worth $378M, up 3.3% from $366M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

International Biotechnology Trust deployed $42.8M of net new capital in Q1 2021, opening 9 new positions and adding to 14 existing holdings. Its largest new stake was Illumina: 16,756 shares worth $6.26M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $18.8M trimmed.

  • International Biotechnology Trust's largest Q1 2021 buy was Illumina: 16,756 shares worth $6.26M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q1 2021, an estimated $19.2M increase.
  • International Biotechnology Trust's biggest Q1 2021 reduction was Acadia Pharmaceuticals, cutting an estimated $18.8M.
  • International Biotechnology Trust fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $15.5M.
  • International Biotechnology Trust's ten largest holdings make up 55% of its $378M portfolio in Q1 2021.
  • International Biotechnology Trust opened 9 new positions and closed 5 in Q1 2021.
  • International Biotechnology Trust's portfolio value rose 3.3% quarter-over-quarter to $378M.

Based on International Biotechnology Trust's 13F filing for Q1 2021, filed 17 May 2021.